Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Evoke Pharma, Inc. EVOK NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
57/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.00
+63.6%

Evoke Pharma, Inc. (EVOK) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $11.00. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is EVOK = $18 (+63.6% upside).

Financials: revenue is $10M, +86.5%/yr average growth. Net income is $5M (loss), growing at +15.2%/yr. Net profit margin is -52.2% (negative). Gross margin is 96.5% (+16.8 pp trend).

Balance sheet: total debt is $5M against $7.0T equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.66 (strong liquidity). Debt-to-assets is 29.5%. Total assets: $18M.

Analyst outlook: 9 / 12 analysts rate EVOK as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).

$18.00
▲ 63.64% Upside
Average Price Target
The 12-month price target for Evoke Pharma, Inc. is $18.00.

EVOK SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EVOK

✓
VALUE Pass
100/100
EVOK trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $18, implying +63.6% from the current price $11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
EVOK: +86.5%/yr revenue is, +15.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet EVOK: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.66 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
EVOK: Gross margin is 96.5% (+16.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 9 / 12 analysts rate EVOK as buy (75%). Analyst consensus target is $18 (+63.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
EVOK: Net profit margin is -52.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.94-11
Volume47.1K
Avg Volume (30D)100.37K
Market Cap$18.95M
Beta (1Y)-0.14
Share Statistics
EPS (TTM)-2.81
Shares Outstanding$1.91M
IPO Date2013-09-25
Employees3
CEOMark A. Kowieski
Financial Highlights & Ratios
Revenue (TTM)$10.25M
Gross Profit$9.89M
EBITDA$-4.85M
Net Income$-5.35M
Operating Income$-5.2M
Total Cash$13.6M
Total Debt$5.16M
Net Debt$-8.44M
Total Assets$17.52M
Price / Earnings (P/E)-3.9
Price / Sales (P/S)1.85
Analyst Forecast
1Y Price Target$18.00
Target High$18.00
Target Low$18.00
Upside+63.6%
Rating ConsensusBuy
Analysts Covering12
Buy 75% Hold 25% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS30049G3020

Price Chart

Track all markets on TradingView
EVOK
Evoke Pharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
1.94 52WK RANGE 11.00

People Also View

RGC
RGC
Regencell Bioscience Holdings Limited
$30.11
-6.61%
 AVDL
AVDL
Avadel Pharmaceuticals plc
$21.64
+0.00%
 AQST
AQST
Aquestive Therapeutics, Inc.
$4.15
-0.95%
 DERM
DERM
Journey Medical Corporation
$5.26
+1.15%
 PROC
PROC
Procaps Group S.A.
$1.01
+100.00%
 JUPW
JUPW
Jupiter Wellness, Inc.
$1.52
+11.76%
 CPIX
CPIX
Cumberland Pharmaceuticals Inc.
$3.18
+1.92%
 IXHL
IXHL
Incannex Healthcare Limited
$3.54
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message